Viatris is a global pharmaceutical company that produces generic, branded, and complex generic medicines across a broad range of therapeutic areas.
| Filer | 13FScore | This quarter | Shares | Value | % of their book |
|---|---|---|---|---|---|
| David Einhorn / Greenlight | 45 | Added +55% | 4,294,920 | $76,105,982 | 2.1% |
| Bridgewater | 55 | Added +27% | 2,151,909 | $38,131,827 | 0.2% |
| Ancora | 42 | Added +100% | 536 | $9,498 | 0.0% |
| Paul Tudor Jones / Tudor | 61 | Added +4269% | 786,358 | $13,934,264 | 0.0% |
| Louis Bacon / Moore | 52 | Trimmed -55% | 1,229,857 | $21,793,066 | 0.4% |
| Larry Robbins / Glenview | 61 | Trimmed -98% | 209,983 | $3,720,899 | 0.1% |
| Steve Cohen / Point72 | 75 | Trimmed -91% | 56,200 | $995,864 | 0.0% |
Every tracked holder of this name, sorted new → added → flat → trimmed. Shares = reported 13F share count; Value as reported (a few managers file values in $thousands). Generated 2026-11-17.